Published in Cancer Res on March 01, 2000
Prostaglandins and cancer. Gut (2005) 3.44
Phenotype and genotype of pancreatic cancer cell lines. Pancreas (2010) 3.06
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia (2009) 2.50
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest (2002) 2.31
Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A (2003) 2.23
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol (2012) 2.06
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol (2007) 1.95
Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer (2006) 1.71
Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol (2015) 1.65
Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci U S A (2002) 1.61
Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem (2002) 1.60
Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem (2001) 1.36
Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res (2010) 1.33
Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia (2001) 1.32
Growth inhibition and apoptosis induction of Sulindac on Human gastric cancer cells. World J Gastroenterol (2001) 1.32
Complete remission of ALK-negative plasma cell granuloma (inflammatory myofibroblastic tumor) of the lung induced by celecoxib: A case report and review of the literature. Oncol Lett (2013) 1.29
Tpl2 is a key mediator of arsenite-induced signal transduction. Cancer Res (2009) 1.26
Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol (2015) 1.24
Is cyclooxygenase-2 the alpha and the omega in cancer? J Clin Invest (2000) 1.22
Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc Natl Acad Sci U S A (2001) 1.21
Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol (2003) 1.20
Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer (2003) 1.16
Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol (2014) 1.15
Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol (2006) 1.13
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer (2005) 1.12
Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut (2008) 1.12
Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin Cancer Res (2005) 1.10
Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. J Pharmacol Exp Ther (2012) 1.10
Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol (2004) 1.10
Targeting the tumor microenvironment: focus on angiogenesis. J Oncol (2011) 1.09
Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. Proc Natl Acad Sci U S A (2008) 1.09
HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium. Br J Cancer (2011) 1.09
COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol Cancer (2008) 1.09
Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia (2001) 1.08
Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy (2012) 1.07
Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. Br J Cancer (2002) 1.07
Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res Treat (2008) 1.07
NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells. Mol Cancer Ther (2009) 1.05
Effect of nimesulide on proliferation and apoptosis of human hepatoma SMMC-7721 cells. World J Gastroenterol (2002) 1.04
The therapeutic implications of clinically applied modifiers of heat shock protein 70 (Hsp70) expression by tumor cells. Cell Stress Chaperones (2008) 1.04
Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. Int J Biol Sci (2007) 1.03
Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer (2006) 1.03
Bowen's disease - a review of newer treatment options. Ther Clin Risk Manag (2008) 1.02
COX-2 and cancer: a new approach to an old problem. Br J Pharmacol (2001) 1.02
Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer (2007) 1.01
Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model. Pharm Res (2006) 1.01
Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin Radiat Oncol (2009) 1.00
Dietary chalcones with chemopreventive and chemotherapeutic potential. Genes Nutr (2011) 1.00
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. Br J Cancer (2011) 0.99
Common colorectal cancer risk variants in SMAD7 are associated with survival among prediagnostic nonsteroidal anti-inflammatory drug users: a population-based study of postmenopausal women. Genes Chromosomes Cancer (2011) 0.99
Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results. Br J Cancer (2006) 0.99
Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer (2008) 0.98
Cyclooxygenase-1 or -2--which one mediates lipopolysaccharide-induced hypothermia? Am J Physiol Regul Integr Comp Physiol (2009) 0.98
Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy. Mol Cancer (2009) 0.97
The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. BMC Cancer (2006) 0.97
An inhibitor of stress-activated MAP-kinases reduces invasion and MMP-2 expression of malignant melanoma cells. Clin Exp Metastasis (2002) 0.97
Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer. Mol Ther (2009) 0.97
Resveratrol and cancer: Challenges for clinical translation. Biochim Biophys Acta (2014) 0.96
Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis. Cancer Res (2010) 0.96
The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma. Clin Exp Metastasis (2014) 0.95
Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4. Cancer (2010) 0.95
Correlation between expression of cyclooxygenase-2 and angiogenesis in human gastric adenocarcinoma. World J Gastroenterol (2003) 0.95
National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms. Neoplasia (2002) 0.95
The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis (2006) 0.94
Celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress. Neuro Oncol (2013) 0.94
Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis (2002) 0.93
Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer (2006) 0.92
Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Dis (2013) 0.92
Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib. Ann Surg (2005) 0.92
Adiponectin deficiency: role in chronic inflammation induced colon cancer. Biochim Biophys Acta (2011) 0.92
Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk women. BMC Cancer (2008) 0.91
Non-steroidal anti-inflammatory drugs in prevention of gastric cancer. World J Gastroenterol (2006) 0.91
Helicobacter pylori CagA: From Pathogenic Mechanisms to Its Use as an Anti-Cancer Vaccine. Front Immunol (2013) 0.91
Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance. World J Gastroenterol (2005) 0.90
COX-2/EGFR expression and survival among women with adenocarcinoma of the lung. Carcinogenesis (2008) 0.89
Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44. Clin Exp Metastasis (2004) 0.89
Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells. World J Gastroenterol (2007) 0.89
Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis. BMC Immunol (2012) 0.89
Astragalus saponins downregulate vascular endothelial growth factor under cobalt chloride-stimulated hypoxia in colon cancer cells. BMC Complement Altern Med (2012) 0.89
Tamoxifen induces regression of estradiol-induced mammary cancer in the ACI.COP-Ept2 rat model. Breast Cancer Res Treat (2008) 0.88
Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery. Ann Surg (2005) 0.88
The effects of nepafenac and amfenac on retinal angiogenesis. Brain Res Bull (2009) 0.88
Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: evaluation of CEA-based cancer vaccines. Mutat Res (2005) 0.88
Targeting the eicosanoid pathway in non-small-cell lung cancer. Expert Opin Ther Targets (2009) 0.88
Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 0.88
CDK/CCN and CDKI alterations for cancer prognosis and therapeutic predictivity. Biomed Res Int (2014) 0.88
Inhibition of cyclooxygenase-2 suppresses the invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 production and activation. Clin Exp Metastasis (2009) 0.88
Inhibition of tumor angiogenesis by oral etoposide. Exp Ther Med (2010) 0.88
Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum. Oncol Rep (2012) 0.87
Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients. BMC Cancer (2011) 0.87
RNAi-mediated knockdown of cyclooxygenase2 inhibits the growth, invasion and migration of SaOS2 human osteosarcoma cells: a case control study. J Exp Clin Cancer Res (2011) 0.87
Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer. BMC Cancer (2006) 0.87
Anti-tumor enhancement of Fei-Liu-Ping ointment in combination with celecoxib via cyclooxygenase-2-mediated lung metastatic inflammatory microenvironment in Lewis lung carcinoma xenograft mouse model. J Transl Med (2015) 0.86
Inflammation and MiR-21 pathways functionally interact to downregulate PDCD4 in colorectal cancer. PLoS One (2014) 0.86
Cyclooxygenase isoenzyme-2 and vascular endothelial growth factor are associated with poor prognosis in esophageal adenocarcinoma. J Gastrointest Surg (2012) 0.86
Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. Neuro Oncol (2008) 0.86
A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest New Drugs (2006) 0.86
Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications. J Clin Pathol (2005) 0.85
COX-2 expression and tumor angiogenesis in thyroid carcinoma patients among northeast Chinese population-result of a single-center study. Int J Med Sci (2012) 0.85
Oleocanthal, a phenolic derived from virgin olive oil: a review of the beneficial effects on inflammatory disease. Int J Mol Sci (2014) 0.85
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (1997) 5.11
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A (1994) 4.15
Some aspects of anal continence and defaecation. Gut (1965) 4.02
Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A (1993) 3.93
The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem (1990) 3.34
The natural history of cigarette smoking: predicting young-adult smoking outcomes from adolescent smoking patterns. Health Psychol (1990) 3.11
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res (1998) 3.11
Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res (1999) 3.00
COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer (2000) 2.94
Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci U S A (1992) 2.92
Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A (1998) 2.71
Inducible plasmid-determined resistance to arsenate, arsenite, and antimony (III) in escherichia coli and Staphylococcus aureus. J Bacteriol (1981) 2.70
Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest (1990) 2.66
Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci U S A (1992) 2.55
Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res (1999) 2.40
A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest (1997) 2.37
Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med (1996) 2.28
Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res (2000) 2.12
Formulation and physical characterization of large porous particles for inhalation. Pharm Res (1999) 2.10
Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science (1998) 2.03
Stimulation of synthesis of ribonucleic acid in sub-apical sections of Avena coleoptile by indolyl-3-acetic acid. Nature (1965) 1.97
The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res (2000) 1.96
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog (1999) 1.95
Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res (2000) 1.88
4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem (2000) 1.84
Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res (2000) 1.84
Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J (1995) 1.74
Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J (1999) 1.64
A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem (1996) 1.61
Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. J Clin Invest (1994) 1.59
Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res (1999) 1.58
A theoretical model of erosion and macromolecular drug release from biodegrading microspheres. J Pharm Sci (1997) 1.58
Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res (1996) 1.58
Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res (2001) 1.56
Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur J Pharmacol (1995) 1.55
Fungal pathogen protection in potato by expression of a plant defensin peptide. Nat Biotechnol (2000) 1.55
Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J Clin Invest (1997) 1.54
Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation. Cancer Res (1999) 1.54
Determinants and nature of intramuscular temperature changes during cold therapy. Am J Phys Med (1975) 1.51
A hypothesis of anal continence. Proc R Soc Med (1965) 1.50
Effect of meal viscosity and nutrients on satiety, intragastric dilution, and emptying assessed by MRI. Am J Physiol Gastrointest Liver Physiol (2001) 1.50
Implantable cardioverter defibrillator utilization among device recipients presenting exclusively with syncope or near-syncope. J Cardiovasc Electrophysiol (1997) 1.42
Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci U S A (2002) 1.41
Impregnation of antibiotic into porous high density polyethylene material (Medpor) using negative pressure. Br J Oral Maxillofac Surg (2006) 1.39
Blood transfusion services. Br J Hosp Med (1991) 1.38
Regulation of prostaglandin production by nitric oxide; an in vivo analysis. Br J Pharmacol (1995) 1.37
Symposium on gastrooesophageal reflux and its complications. 1. Definitions, the antireflux mechanism, and symptoms. Gut (1973) 1.36
The pathology of a cricopharyngeal dysphagia. Histopathology (1979) 1.35
Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors. J Clin Invest (1995) 1.33
A mechanistic study of ultrasonically-enhanced transdermal drug delivery. J Pharm Sci (1995) 1.30
The natural history of cigarette smoking and young adult social roles. J Health Soc Behav (1992) 1.30
Early histologic changes in lower lumbar discs and facet joints and their correlation. Eur Spine J (2000) 1.29
Complementation analysis in Pseudomonas aeruginosa of the transfer genes of the wide host range R plasmid R18. Plasmid (1981) 1.28
A quantitative assessment of results with the Angelchik prosthesis. Ann R Coll Surg Engl (1985) 1.28
COX-2 inhibitors. A new class of antiangiogenic agents. Ann N Y Acad Sci (1999) 1.25
Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Br J Pharmacol (1989) 1.24
Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase. Proc Natl Acad Sci U S A (1994) 1.23
Four pathways to young-adult smoking status: adolescent social-psychological antecedents in a midwestern community sample. Health Psychol (1991) 1.22
The neonatal testosterone surge: a comparative study. Arch Int Physiol Biochim Biophys (1992) 1.22
Role of cyclooxygenases in angiogenesis. Curr Med Chem (2000) 1.20
Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther (1997) 1.18
Isolation of low density lipoprotein from atherosclerotic vascular tissue of Watanabe heritable hyperlipidemic rabbits. Arteriosclerosis (1989) 1.17
Diminished 5alpha-reductase activity in extracts of fibroblasts cultured from patients with familial incomplete male pseudohermaphroditism, type 2. J Biol Chem (1975) 1.16
Effects of aging on the primate visual system: spatial and temporal processing by lateral geniculate neurons in young adult and old rhesus monkeys. J Neurophysiol (1994) 1.14
A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem J (2001) 1.14
Degeneration of the cervical disc: histology compared with radiography and magnetic resonance imaging. Neuroradiology (2005) 1.13
Steroid 5alpha-reductase in cultured human fibroblasts. Biochemical and genetic evidence for two distinct enzyme activities. J Biol Chem (1976) 1.12
In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophages. J Pharmacol Exp Ther (1994) 1.12
Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Cancer (1980) 1.12
Parent educational attainment and adolescent cigarette smoking. J Subst Abuse (1992) 1.11
The oesophagus. Gut (1971) 1.11
Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat. Endocrinology (1996) 1.08
Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am (1996) 1.08
The anti-reflux mechanism after cardiomyotomy. Thorax (1978) 1.07
Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3',5'-cyclic monophosphate degradation. J Clin Invest (1990) 1.07
Studies on the mechanism of 3 alpha-androstanediol-induced growth of the dog prostate. Endocrinology (1978) 1.06
Gastric response to increased meal viscosity assessed by echo-planar magnetic resonance imaging in humans. J Nutr (2000) 1.06
Thromboxane synthase is preferentially conserved in activated mouse peritoneal macrophages. J Clin Invest (1985) 1.06
Radiation dose in radiography, CT, and arthrography of the temporomandibular joint. AJR Am J Roentgenol (1987) 1.06
Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2. Mol Carcinog (1998) 1.05
Distribution and characterization of cyclooxygenase immunoreactivity in the ovine brain. J Comp Neurol (1992) 1.05
Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol (1998) 1.05
Testosterone levels in plasma and testes of neonatal mice. J Steroid Biochem (1988) 1.04
Caseous lymphadenitis vaccine development: site-specific inactivation of the Corynebacterium pseudotuberculosis phospholipase D gene. Vaccine (1995) 1.04